Reports Q3 revenue $30.4M, consensus $30.39M. “Our third quarter results were in line with the expectations we set in October, and our focus remains on ensuring the benefits of Tablo reach as many providers and patients as possible this year and well into the future,” said Leslie Trigg, Chair and Chief Executive Officer. “All of the structural tailwinds for Tablo remain firmly in place, and we have high confidence in our ability to generate sustained long-term growth, achieve our gross margin goals, and reach profitability.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OM:
- Netflix downgraded, Applied Materials upgraded: Wall Street’s top analyst calls
- Outset Medical downgraded to Underperform from Buy at BofA
- Outset Medical price target lowered to $17 from $29 at RBC Capital
- Outset Medical price target lowered to $9 from $32 at TD Cowen
- Outset Medical price target lowered to $6 from $26 at Stifel
